Abstract
Legislation and prospective legislative proposals in for instance the USA, Europe, and Japan require, or may require that chemicals are tested for their ability to disrupt the hormonal systems of mammals. Chemicals found to test positive are considered to be endocrine active substances (EAS) and may be putative endocrine disruptors (EDs). To date, there is still little or no experience with incorporating metabolic and toxicokinetic aspects into in vitro tests for EAS. This is a situation in sharp contrast to genotoxicity testing, where in vitro tests are routinely conducted with and without metabolic capacity. Originally prepared for the Organisation of Economic Cooperation and Development (OECD), this detailed review paper reviews why in vitro assays for EAS should incorporate mammalian systems of metabolism and metabolic enzyme systems, and indicates how this could be done. The background to ED testing, the available test methods, and the role of mammalian metabolism in the activation and the inactivation of both endogenous and exogenous steroids are described. The available types of systems are compared, and the potential problems in incorporating systems in in vitro tests for EAS, and how these might be overcome, are discussed. Lastly, some recommendations for future activities are made.
Keywords: Endocrine disruption, endocrine active substances, metabolism, cytochrome P450, estrogenicity, androgenicity
Current Drug Metabolism
Title: The Use of Metabolising Systems for In Vitro Testing of Endocrine Disruptors
Volume: 9 Issue: 8
Author(s): M. N. Jacobs, W. Janssens, U. Bernauer, E. Brandon, S. Coecke, R. Combes, P. Edwards, A. Freidig, A. Freyberger, R. Kolanczyk, C. Mc Ardle, O. Mekenyan, P. Schmieder, T. Schrader, M. Takeyoshi and B. van der Burg
Affiliation:
Keywords: Endocrine disruption, endocrine active substances, metabolism, cytochrome P450, estrogenicity, androgenicity
Abstract: Legislation and prospective legislative proposals in for instance the USA, Europe, and Japan require, or may require that chemicals are tested for their ability to disrupt the hormonal systems of mammals. Chemicals found to test positive are considered to be endocrine active substances (EAS) and may be putative endocrine disruptors (EDs). To date, there is still little or no experience with incorporating metabolic and toxicokinetic aspects into in vitro tests for EAS. This is a situation in sharp contrast to genotoxicity testing, where in vitro tests are routinely conducted with and without metabolic capacity. Originally prepared for the Organisation of Economic Cooperation and Development (OECD), this detailed review paper reviews why in vitro assays for EAS should incorporate mammalian systems of metabolism and metabolic enzyme systems, and indicates how this could be done. The background to ED testing, the available test methods, and the role of mammalian metabolism in the activation and the inactivation of both endogenous and exogenous steroids are described. The available types of systems are compared, and the potential problems in incorporating systems in in vitro tests for EAS, and how these might be overcome, are discussed. Lastly, some recommendations for future activities are made.
Export Options
About this article
Cite this article as:
Jacobs N. M., Janssens W., Bernauer U., Brandon E., Coecke S., Combes R., Edwards P., Freidig A., Freyberger A., Kolanczyk R., Mc Ardle C., Mekenyan O., Schmieder P., Schrader T., Takeyoshi M. and Burg van der B., The Use of Metabolising Systems for In Vitro Testing of Endocrine Disruptors, Current Drug Metabolism 2008; 9 (8) . https://dx.doi.org/10.2174/138920008786049294
DOI https://dx.doi.org/10.2174/138920008786049294 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular and Molecular Targeted Drug Delivery: Nanochemistry in Medical Theranostics
Current Topics in Medicinal Chemistry Cell-penetrating Peptide-mediated Nanovaccine Delivery
Current Drug Targets Expression and Functions of LRP-2 in Central Nervous System: Progress in Understanding its Regulation and the Potential Use for Treatment of Neurodegenerative Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry Mitochondrial Therapeutics for Cardioprotection
Current Pharmaceutical Design Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets Effects of Amine Oxidases in Allergic and Histamine-Mediated Conditions
Recent Patents on Inflammation & Allergy Drug Discovery The Role of the Complex USP1/WDR48 in Differentiation and Proliferation Processes in Cancer Stem Cells
Current Stem Cell Research & Therapy Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents
Current Medicinal Chemistry Development of Arene Ruthenium Antitumor Complexes
Mini-Reviews in Medicinal Chemistry Ulipristal Acetate (Esmya) in the Management of Heavy Menstrual Bleeding Associated with Fibroids: A Case Series
Current Women`s Health Reviews The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review
Letters in Drug Design & Discovery Atrial Fibrillation Recurrence: The Roles of Hypertension, Duration of Atrial Fibrillation Disease, and Prolonged Signal-Averaged P Wave Duration
Current Cardiology Reviews Targeting Matrix Metalloproteinases in Acute Inflammatory Shock Syndromes
Combinatorial Chemistry & High Throughput Screening Pathological and Therapeutic Aspects of Long Noncoding RNAs in Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Chemosensitization and Immunosensitization of Resistant Cancer Cells to Apoptosis and Inhibition of Metastasis by the Specific NF-κB Inhibitor DHMEQ
Current Pharmaceutical Design Trace of Long Non-Coding RNAs in Signaling Pathways in Thyroid Cancer
Current Signal Transduction Therapy Immune Functions of Glia and Neurons in the Central Nervous System
Current Immunology Reviews (Discontinued) DNA Double Strand Break Repair - Related Synthetic Lethality
Current Medicinal Chemistry